Raymond James & Associates Raises Stock Position in DaVita Inc. (NYSE:DVA)

Raymond James & Associates increased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 93.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,316 shares of the company's stock after purchasing an additional 15,138 shares during the period. Raymond James & Associates' holdings in DaVita were worth $5,134,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of DVA. Blue Trust Inc. grew its stake in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company's stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Capital Investment Advisors LLC purchased a new position in DaVita during the third quarter valued at $213,000. Vontobel Holding Ltd. grew its stake in DaVita by 17.2% during the third quarter. Vontobel Holding Ltd. now owns 2,243 shares of the company's stock valued at $368,000 after acquiring an additional 329 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in DaVita during the third quarter valued at $97,000. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in DaVita by 27.3% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,630 shares of the company's stock valued at $267,000 after acquiring an additional 350 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Insider Activity at DaVita

In related news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael David Staffieri sold 9,539 shares of the business's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares of the company's stock, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 in the last 90 days. 2.00% of the stock is owned by corporate insiders.

DaVita Trading Up 1.3 %

Shares of DVA stock traded up $1.78 during trading hours on Friday, reaching $141.59. 1,064,258 shares of the stock were exchanged, compared to its average volume of 822,639. DaVita Inc. has a 12-month low of $76.64 and a 12-month high of $168.50. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 15.78. The company's 50-day moving average price is $157.71 and its 200-day moving average price is $146.05. The firm has a market capitalization of $11.61 billion, a price-to-earnings ratio of 15.27, a price-to-earnings-growth ratio of 0.79 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same period in the prior year, the firm posted $2.85 earnings per share. DaVita's revenue for the quarter was up 4.6% on a year-over-year basis. As a group, equities analysts anticipate that DaVita Inc. will post 9.73 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DVA shares. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a research note on Wednesday, July 24th. Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 7th. Finally, Barclays lifted their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of "Hold" and an average target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.